AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Innovation Article
PDF (1.5 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Guideline | Open Access

Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

Abstract

Antibody‐drug conjugates (ADCs) are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker. The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects. It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.

Graphical Abstract

Keywords

malignant tumorsantibody‐drug conjugatesmonoclonal antibodiescytotoxic drugssafety management

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Innovation
Volume 1 Issue 1,
June 2022
Pages 3-24
DOI: 10.1002/cai2.8

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innovation, 2022, 1(1): 3-24. https://doi.org/10.1002/cai2.8

3009

Views

93

Downloads

14

Crossref

14

Web of Science

13

Scopus
Received: 08 April 2022
Accepted: 23 April 2022
Published: 19 June 2022
© 2022 The Authors.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.